Corvus Pharmaceuticals, Inc.
Every calculator, already run for CRVS
Open the full toolkit →You have the numbers on CRVS. Get the argument.
A written report on which of these readings actually decide the outcome for Corvus Pharmaceuticals, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
8 analysts covering CRVSOwnership & short interest
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the…
CRVS — frequently asked
Is CRVS a buy right now?
Wall Street's consensus rating on Corvus Pharmaceuticals, Inc. is Strong Buy across 8 analysts, with a mean price target of $33.14 (+138% vs. the current $13.93). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is CRVS's next earnings date?
Corvus Pharmaceuticals, Inc. is next scheduled to report earnings around Aug 6, 2026. A full CRVS research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
Compare Corvus Pharmaceuticals, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Corvus Pharmaceuticals, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full CRVS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Corvus Pharmaceuticals, Inc., in minutes. 3 free reports included with every account — no credit card required.